Skip to main content

Table 3 Univariable associations of outcome measures and clinical variables: Gray’s test for LC, logrank test for lung PFS, distant PFS and OS

From: Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases

Endpoint

Local control

Lung PFS

Distant PFS

Overall survival

Clinical variables

Hazard ratio (95% CI)

p value

Hazard ratio (95% CI)

p value

Hazard ratio (95% CI)

p value

Hazard ratio (95% CI)

p value

Primary histology (adeno vs other)

0.52 (0.24–1.12)

0.093

0.49 (0.27–0.87)

0.023

0.73 (0.38–1.41)

0.44

0.28 (0.12–0.67)

0.009

Primary tumor site (lung vs other)

1.94 (0.90–4.16)

0.10

1.88 (1.06–3.33)

0.043

1.66 (0.84–3.29)

0.20

5.77 (2.39–13.94)

< 0.001

Primary tumor site (GI vs other)

0.36 (0.15–0.90)

0.029

0.66 (0.39–1.14)

0.17

0.86 (0.45–1.64)

0.77

0.24 (0.10–0.54)

0.0015

Prior chemotherapy (yes vs no)

3.25 (0.79–13.50)

0.084

1.09 (0.59–2.02)

0.90

0.96 (0.46–1.98)

0.95

0.78 (0.31–2.01)

0.79

Age > 65 (yes vs no)

0.49 (0.21–1.14)

0.090

0.94 (0.55–1.60)

0.92

0.65 (0.34–1.24)

0.25

0.95 (0.42–2.16)

0.93

Performance status (1+ vs 0)

3.63 (0.88–14.90)

0.056

0.76 (0.40–1.46)

0.52

2.10 (1.04–4.25)

0.060

2.58 (1.01–6.58)

0.082

Gender (male vs female)

2.26 (0.94–5.44)

0.060

0.93 (0.54–1.59)

0.90

0.92 (0.49–1.72)

0.92

0.85 (0.37–1.93)

0.86